Yahoo · Sep 1, 2026
Why Is ISRG Investing More Aggressively in R&D Despite Macro Headwinds?
Intuitive Surgical is boosting R&D despite macro headwinds, targeting AI, robotics and new procedures to expand its market and drive long-term growth.
GK
NYSE · GKOS
Glaukos Corporation
Healthcare · Medical - Devices
$167.25
Down-$3.13 (-1.84%)
Updated Sep 12, 2026, 5:52 AM
SID Score
5.7/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 6.27B
- P/E ratio
- -71.17
- Dividend yield
- 0.00%
- 52-week range
- $95.87 – $191.62
- Volume
- 552.31K
- Avg. volume
- 1.14M
Price performance
GKOS price history
1M range · 20 trading sessions · Daily adjusted prices
GKOS closed at $167.25 after 20 trading sessions, down 9.36% for the selected period.
- Last close
- $167.25
- Period change
- -9.36%
- Period low
- $167.25
- Period high
- $189.55
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $174.12 | $175.375 | $166.74 | $167.25 | 552.31K |
| Sep 10, 2026 | $176.50 | $179.96 | $169.26 | $170.38 | 1.01M |
| Sep 9, 2026 | $183.15 | $183.33 | $178.52 | $179.79 | 587.94K |
| Sep 8, 2026 | $175.55 | $185.35 | $172.98 | $185.04 | 1.16M |
| Sep 4, 2026 | $177.80 | $181.52 | $175.135 | $177.47 | 572.54K |
| Sep 3, 2026 | $180.80 | $181.295 | $178.72 | $180.35 | 610.19K |
| Sep 2, 2026 | $176.87 | $182.2798 | $176.35 | $179.53 | 768.72K |
| Sep 1, 2026 | $179.97 | $180.14 | $175.33 | $176.70 | 507.24K |
| Aug 31, 2026 | $178.67 | $180.075 | $174.28 | $179.56 | 455.57K |
| Aug 28, 2026 | $181.10 | $182.225 | $177.77 | $179.87 | 553.53K |
| Aug 27, 2026 | $178.51 | $183.315 | $178.43 | $181.91 | 442.31K |
| Aug 26, 2026 | $180.11 | $181.89 | $176.82 | $180.57 | 506.04K |
| Aug 25, 2026 | $186.21 | $187.14 | $179.20 | $181.39 | 639.69K |
| Aug 24, 2026 | $184.13 | $186.88 | $181.75 | $185.65 | 622.29K |
| Aug 21, 2026 | $185.00 | $187.60 | $183.68 | $184.89 | 440.1K |
| Aug 20, 2026 | $187.73 | $191.62 | $183.245 | $184.89 | 791.87K |
| Aug 19, 2026 | $186.00 | $190.06 | $185.96 | $189.55 | 505.43K |
| Aug 18, 2026 | $185.00 | $186.66 | $175.04 | $184.15 | 625.63K |
| Aug 17, 2026 | $183.55 | $186.03 | $181.84 | $185.62 | 734.77K |
| Aug 14, 2026 | $189.89 | $190.00 | $184.22 | $184.53 | 743.41K |
Latest GKOS news
The latest Smart Investors Daily articles mentioning GKOS.
Stock researchCompany · Overview
GKOS research
Overview
Company profile and research snapshot.
Company profile
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $121.38
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | BTIG | Buy | — |
| Jul 30, 2026 | Needham | Buy | — |
| Jul 30, 2026 | Wells Fargo | Overweight | — |
| Jul 30, 2026 | BTIG | Buy | — |
| Jul 30, 2026 | Stifel | Buy | — |
News briefing
No generated briefing is available yet.
ChartMill · Sep 1, 2026
Glaukos (NYSE:GKOS) Passes Minervini Trend Template and High-Growth Momentum Screen
GKOS fits a Minervini Trend Template + High Growth Momentum screen: strong uptrend, near 52-week high, top-tier relative strength, and accelerating revenue and EPS growth.
Yahoo · Aug 28, 2026
Glaukos (GKOS) Up 8% Since Last Earnings Report: Can It Continue?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Benzinga · Aug 25, 2026
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized basis producing an average annual return of 26.17%. Currently, Glaukos has a market capitalization of $10.97 billion.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
